Role of Protein Kinase C in Colon Carcinogenesis
Role of Protein Kinase C in Colon Carcinogenesis
批准号:
7122483
负责人:
Alan P. Fields
金额:
$42.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-02 至 2009-06-30
关键词:
athymic mousebiological signal transductioncarcinogenesiscell growth regulationcell linecell proliferationclinical researchcolon neoplasmsgastrointestinal epitheliumgene expressiongene interactiongenetic regulationgenetically modified animalsisozymesmetastasismolecular oncologyneoplasm /cancer geneticsneoplasm /cancer invasivenessneoplastic celloncogenesprotein kinase Cprotein protein interactionprotein structure functiontransforming growth factors
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Colon cancer is the second leading cause of cancer death in the United States. It arises by a multi-step process involving progressive changes in signaling pathways that regulate epithelial cell proliferation, differentiation and survival. PKCbetaII induces hyperproliferation in the colon, and is required for early steps in colon carcinogenesis in vivo. PKCbetaII induces resistance to the growth inhibitory effects of TGFbeta in rat intestinal epithelial (RIE) cells through activation of a novel PKCbetaII->Cox-2->TGFbetaRII signaling axis. PKCbetaII also induces an invasive phenotype in RIE cells through activation of a PKCbetaII->Ras/Mek->PKCI/Rac1 signaling pathway. The overall hypothesis to be tested in this proposal is that PKCbetaII is required for the transformed phenotype in human colon cancer cells. Aim 1 will test the hypothesis that PKCbetaII confers TGFbeta resistance on human colon cancer cells by activating the PKCbetaII->Cox-->?TGFbetaRII signaling axis. Aim 2 will test the hypothesis that PKCbetaII is important for anchorage-independent growth and invasion of human colon cancer cells in vitro, and for tumorigenicity and metastasis in vivo. PKCbetaII expression will also be assessed in human colon cancers and compared with clinical outcome. Aim 3 will test the hypothesis that PKCII is required for K-Ras-mediated colon carcinogenesis in vivo using two complementary transgenic K-Ras mouse models crossed to PKCbeta KO mice. Aim 4 will test the hypothesis that PKCbetaII and PKC/I collaborate to promote colon carcinogenesis in vivo. The role of PKC/I in PKCbetaII-mediated colon carcinogenesis will be assessed in transgenic PKCbetaII mice crossed to transgenic mice expressing kinase-deficient PKC/I. Synergism between PKCbetaII and PKC/I in colon cancer progression, invasion and metastasis will be assessed in transgenic PKCbetaII mice crossed to mice expressing constitutively-active PKC/I. These studies will determine the role of PKCbetaII in human colon cancer cell transformation, the signaling mechanisms by which PKCbeta/II contributes to cellular transformation, and the relationship between PKCbetaII, PKC? and oncogenic K-Ras in promoting colon carcinogenesis in vivo. They will also assess PKCbetaII as a potential therapeutic target and prognostic marker in colon cancer, and develop new genetic models of colon cancer that may be suitable for studying all stages of colon carcinogenesis from initiation to invasive carcinoma in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating cells of origin and oncogenic modifiers of 3q26-driven LUSC
-
批准号:10593501
-
项目类别:
-
资助金额:$7.37万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10653913
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10296271
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
-
批准号:10413236
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2021
-
负责人:Alan P. Fields
-
依托单位:
Therapeutic targeting of Kras-driven Lung Adenocarcinoma
-
批准号:9303312
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2016
-
负责人:Alan P. Fields
-
依托单位:
The pathophysiology and palliation of the paclitaxel-induced acute pain syndrome
-
批准号:8930932
-
项目类别:
-
资助金额:$17.21万
-
财政年份:2014
-
负责人:Alan P. Fields
-
依托单位:
Combined PKCiota and mTOR inhibition for treatment of advanced squamous lung canc
-
批准号:8299006
-
项目类别:
-
资助金额:$32.77万
-
财政年份:2011
-
负责人:Alan P. Fields
-
依托单位:
Combined PKCiota and mTOR inhibition for treatment of advanced squamous lung canc
-
批准号:8110919
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2011
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8244684
-
项目类别:
-
资助金额:$8.42万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8100459
-
项目类别:
-
资助金额:$19.62万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:7939191
-
项目类别:
-
资助金额:$16.86万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Atypical PKC signaling in lung cancer stem cells
-
批准号:8142296
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2010
-
负责人:Alan P. Fields
-
依托单位:
Lipid Signaling Pathways in Cancer
-
批准号:7748739
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2009
-
负责人:Alan P. Fields
-
依托单位:
Lipid Signaling Pathways in Cancer
-
批准号:7922156
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2009
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6800958
-
项目类别:
-
资助金额:$2.83万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6530100
-
项目类别:
-
资助金额:$0.96万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6395006
-
项目类别:
-
资助金额:$3.81万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
LIPID SIGNALLING IN THE CELL NUCLEUS
-
批准号:6199584
-
项目类别:
-
资助金额:$3.78万
-
财政年份:2000
-
负责人:Alan P. Fields
-
依托单位:
Protein Kinase C Signaling Mechanisms in Cancer
-
批准号:10417167
-
项目类别:
-
资助金额:$46.94万
-
财政年份:1999
-
负责人:Alan P. Fields
-
依托单位:
Protein Kinase C Signaling Mechanisms in Cancer
-
批准号:9248796
-
项目类别:
-
资助金额:$39.13万
-
财政年份:1999
-
负责人:Alan P. Fields
-
依托单位:
海外基金